Transperineal ultrasound-guided prostate biopsy is safe even when patients are on combination antiplatelet and/or anticoagulation therapy

To assess whether hemorrhagic complications associated with transperineal prostate biopsy increased in patients on antiplatelet and/or anticoagulant therapy. In total, 598 consecutive patients underwent transperineal prostate biopsy. The medication group comprised patients who took anti-thromboembol...

Full description

Saved in:
Bibliographic Details
Published in:BMC urology 2017-07, Vol.17 (1), p.53-53, Article 53
Main Authors: Saito, Kimitoshi, Washino, Satoshi, Nakamura, Yuhki, Konishi, Tsuzumi, Ohshima, Masashi, Arai, Yoshiaki, Miyagawa, Tomoaki
Format: Article
Language:English
Subjects:
Aged
Anticoagulant
Anticoagulants
Anticoagulants - therapeutic use
Antiplatelet
Antiplatelet therapy
Biopsy
Bleeding
Cardiovascular Diseases - complications
Cardiovascular Diseases - drug therapy
Care and treatment
Classification
Comparative analysis
Complication
Complications and side effects
Dosage and administration
Drug Therapy, Combination
Dual antiplatelet therapy
Hematuria
Hemorrhage
Humans
Image-Guided Biopsy - methods
Male
Multivariate analysis
NMR
Nuclear magnetic resonance
Patient Safety
Perineum
Platelet Aggregation Inhibitors - therapeutic use
Prevention
Prostate
Prostate - pathology
Prostate biopsy
Prostate cancer
Prostatic Neoplasms - complications
Prostatic Neoplasms - pathology
Retrospective Studies
Risk factors
Thromboembolism
Transperineal prostate biopsy
Ultrasonography, Interventional
Ultrasound
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess whether hemorrhagic complications associated with transperineal prostate biopsy increased in patients on antiplatelet and/or anticoagulant therapy. In total, 598 consecutive patients underwent transperineal prostate biopsy. The medication group comprised patients who took anti-thromboembolic agents, and the control group comprised those who did not take these agents. No anti-thromboembolic agent was stopped before, during, or after prostate biopsy in the medication group. Complications developing in both groups were compared and classified using the modified Clavien classification system. Subgroup analyses to compare complications in patients taking single antiplatelet, single anticoagulant, and dual antiplatelet and/or anticoagulant agents, and multivariate analyses to predict bleeding risk were also performed. Of the 598 eligible patients, 149 comprised the medication group and 449 comprised the control group. Hematuria (Grade I) developed in 88 (59.1%) and 236 (52.5%) patients in the medication and control group, respectively (p = 0.18). Clot retention (Grade I) was more frequently observed in the medication group than the controls (2.0% versus 0.2%, respectively, p 
ISSN:1471-2490
1471-2490
DOI:10.1186/s12894-017-0245-z